Lys295
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys295  -  DAPK1 (human)

Site Information
AsAVNMEkFkKFAAR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3740687

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
lung cancer ( 2 , 3 ) , non-small cell lung cancer ( 2 , 3 ) , non-small cell lung adenocarcinoma ( 2 , 3 )
Relevant cell line - cell type - tissue:

References 

1

Li Y (2007) CST Curation Set: 2696; Year: 2007; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

comb b (2007) CST Curation Set: 2621; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

comb b (2007) CST Curation Set: 2573; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated &'||' TSA; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info